Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of primary open-angle glaucoma or ocular hypertension in each eye
Requires bilateral treatment with an IOP-lowering medication
Best corrected visual acuity of 20/100 or better in each eye
You may not be if
Use of oral, intramuscular, intravenous or topical ophthalmic corticosteroids within 2 months
Inability to fast for up to 10 hours
Prior refractive laser surgery (eg, LASIK, radial keratectomy, photorefractive keratectomy)
Intraocular surgery or IOP-lowering laser surgery (eg, laser trabeculoplasty) within 6 months
Current or anticipated use of artificial tears or any ocular medications aside from study medications during study
Anticipated wearing of contact lenses during study
Clareo Health | Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
